Maspin is a novel serine protease inhibitor (serpin) with tumor suppressive activity. To date, despite the mounting evidence implicating the potential diagnostic/prognostic and therapeutic value of maspin in breast and prostate carcinoma, the lack of a suitable animal model hampers the in vivo investigation on the role of maspin at dierent stages of tumor progression. In this study, we used MMTV/TGF-a transgenic mouse model to study the expression pro®le of maspin in mammary tumor progression.
Introduction
Maspin is a novel serine protease inhibitor (serpin) initially identi®ed in normal mammary epithelial cells . Several subsequent studies have con®rmed the down-regulation of maspin in invasive breast carcinoma and breast tumor metastases, as well as in an array of established breast carcinoma cell lines Sager et al., 1994) . In vitro analyses suggest that the expression of maspin may be tightly regulated by a complex mechanism at the transcriptional level. Recent work by Zou et al. (2000) revealed a direct activation of maspin expression by the tumor suppressor gene p53 in both prostatic and mammary carcinoma cell lines, suggesting a role of maspin in p53-mediated tumor suppression. Further biological studies have shown that recombinant maspin inhibits the motility and invasion of both breast and prostate carcinoma cell lines in vitro (Sheng et al., , 1996 . Biochemical evidence suggests that maspin acts as a potent inhibitor of surface-bound tissue type plasminogen activator (tPA) (Sheng et al., 1998) and cellassociated urokinase type plasminogen activator (McGowen et al., 2000) . Given the important role of proteolysis during tumor cell migration and invasion, it is likely that maspin inhibits tumor cell motility and invasion, at least in part by inhibiting the paracellular plasminogen activation.
To further explore the clinical application of maspin in human cancer, it is critical to understand the in vivo biological function of maspin in tumor progression. To this end several animal models have been used in previous studies. For example, endogenous expression of maspin inhibits the growth and metastasis of orthotopic breast tumor xenograft in nude mice Sager et al., 1994) . Recombinant maspin-GST fusion protein was shown to block the angiogenesis induced by subcutaneous prostatic tumor xenograft in nude mice (Zhang et al., 2000) . In addition, an earlier study by showed that mammary speci®c maspin overexpression in transgenic mice severely disrupted the mammary gland development, possibly by preventing cell migration. While these in vivo data provide valuable insight into the biological function of maspin at dierent pathophysiological stages of the mammary gland, none of those animal models is suitable for a detailed assessment of the regulation as well as the role of maspin in the entire course of breast carcinogenesis in vivo.
One of the most powerful models used to examine multistage carcinogenesis has been MMTV/TGF-a transgenic mouse. Elevated levels of TGF-a have been detected in transformed keratinocytes and in a variety of naturally occurring human tumor types (Reddy et al., 1994; Gottlieb et al., 1988) . In addition, the role of TGF-a in neoplasia has been con®rmed in a variety of experimental systems, including transgenic mice in which initially hyperplasia and later neoplasia of liver and mammary glands were observed (Sandgren et al., 1990; Jhappan et al., 1990; Matsui et al., 1990) .
TGF-a is a 50 amino acid 5.6 kDa secreted polypeptide that is cleaved from a large integral membrane glycoprotein. The matured TGF-a molecule shares 35% sequence homology with epidermal growth factor (EGF), binds to the same receptor, and has similar biologic eects (Derynck, 1988) . A commonly cited action of both TGF-a and EGF is that they act as potent mitogens in a number of epithelial cell systems (Carpenter and Cohen, 1979) . The transgenic studies further demonstrated a proliferative role for TGF-a in the development of mammary neoplasia, cooperating with c-myc/TGF-a and Neu oncogenes (Lenferink et al., 2000; Rose-Hellekant and Sandgren, 2000) . On the other hand, inhibitory and modulating agents of the EGFR signaling pathways such as anti-EGFR antibodies and speci®c protein kinase inhibitors have been shown to prevent the development of TGF-a-induced neoplasia and tumor formation (Lenferink et al., 2000; Rose-Hellekant and Sandgren, 2000) .
In this study, we evaluated the role of maspin as a tumor suppressor using MMTV/TGF-a transgenic mouse model, which show a range of abnormalities in the mammary gland including lobular hyperplasia, adenomas, hyperkeratosis and mammary carcinoma. Using a combination of immunohistochemistry and in situ hybridization, we show that both normal myoepithelial cells and normal ductal epithelial cells express maspin at a high level. Hyperplastic mammary epithelium and mammary carcinoma in situ (DCIS) expressed a moderate level of maspin. However more malignant stage of tumors such as invasive carcinoma show a signi®cant reduction or total loss of maspin. Taken collectively, the inherent multi-stage nature of breast carcinogenesis in TGF-a transgenic mice provided us a valuable system to assess the level of maspin in dierent stages of tumor progression in the same tumor such as hyperplasia (ductal or lobular), carcinoma in situ, or invasive carcinoma.
Results
Incidence of sporadic mammary carcinoma is increased in MMTV/TGF-a transgenic mice Homozygous TGF-a transgenic mice were identi®ed by southern blot analysis of tail DNA, and by 100% transmission of the gene when bread with nontransgenic mice (data not shown). In transgenic mice, TGF-a RNA expression was con®rmed by RNase protection analyses. High levels of TGF-a expression were seen in mammary gland and a relatively low level of TGF-a was detected in sebaceous glands and lungs of transgenic multiparous females (Figure 1 ). In contrast, age-matched non-transgenic multiparous females exhibited low levels of TGF-a expression in mammary glands and no signal in sebaceous gland and lung.
The mammary glands from transgenic or nontransgenic virgin females mice (4 weeks) showed no alveolar development. While the non-transgenic mice were not symptomatic throughout their lives, all 50 female transgenic mice used showed signi®cant breast hyperplasia after multiple pregnancies. Twelve of these transgenic mice developed hyperkeratosis and bilateral lumps in their mammary glands. Histologic examination of whole mount tissues revealed signi®cant alveolar hyperplasia throughout the entire mammary glands in the transgenic but not in nontransgenic mice (data not shown). Histologic examination revealed that some of the TGF-a-induced mammary tumors developed breast and sebaceous gland carcinoma as shown in Figure 2 . Although these transgenic mice did no have distal metastases, ®ve of them developed invasive breast carcinoma at 6 ± 8 months of age, as shown in Figure 3 .
Maspin expression inversely correlates with the mammary tumor progression in MMTV/TGF-a transgenic mice
In transgenic mouse group, each tumor specimen had multiple regions of hyperplasia and carcinoma in situ. Since the mammary tumors developed are rather small in size, it is very dicult to extract sucient amount of either protein or RNA for quantitative comparison of maspin expression at a gross level by immunoblotting or Northern blotting. To investigate the expression and Figure 1 Targeted expression of TGF-a in MMTV/TGF-a transgenic mice. Ribonuclease Protection Analysis of TGF-a transgene expression in various mouse tissues. Total RNA from mouse tissues was hybridized to uniformly labeled TGF-a probe, subjected to RNase digestion, electrophoresed in denaturing polyacrylamide gel, and exposed to autoradiographic ®lm. The detected band was a fragment of TGF-a transgene the localization of maspin protein in mouse breast tumor progression, we performed semi-quantitative immunohistochemical staining on the whole mount mammary tissues from ®ve MMTV/TGF-a transgenic mice and two age-matched nontransgenic mice. Figure  2 shows representative immunohistochemical staining results. As can be seen, the oligopeptide-derived polyclonal antibody against maspin, Abs4A, exhibited a speci®c immunoreactivity with normal myoepithelial cells and normal luminal epithelial cells (Figure 2b ). The parallel immunostaining with the preimmune serum gave rise to a negative staining pattern ( Figure  2a) . Furthermore, maspin expression appeared to be cytoplasmic in mammary epithelial cells and was not found in the stroma. As compared to normal mammary epithelium, mammary hyperplasia exhibited a moderate level of maspin expression (Figure 2c ), while mammary carcinoma cells showed little or no maspin immunoreactivity (Figure 2d arrow) . Microscopic examination using a higher magni®cation indicated that the loss of maspin expression was associated with invasive mammary carcinoma ( Figure  3b ). In all tumor samples from the transgenic group (5/ 5), consistent dierential expression of maspin was observed.
To address whether maspin was speci®cally produced by mammary epithelial cells and whether maspin was dierentially expressed at the mRNA level, in-situ hybridization was performed with the whole mount mammary tissues. While the sense-strand of maspin cDNA did not give rise to detectable signal (data not shown), a strong positive staining of maspin mRNA was detected in benign luminal and the myoepithelial cells (Figure 4a ). Hyperplastic mammary epithelium featured heterogeneous maspin staining of a moderate intensity (Figure 4b ). Mammary carcinoma in situ and invasive carcinoma cells expressed little or no maspin mRNA (Figure 4c ). The stroma of both transgenic and Figure 3 Maspin expression is down-regulated in invasive mammary carcinoma. Microscopic examination at higher magni®cation shows maspin present in mammary carcinoma in situ (a), but lost in invasive mammary carcinoma (b) of TGF-a transgenic mice. Maspin detected by immunohistochemical staining gives rise to the reddish brown-color. The cell nuclei are counter-stained blue non-transgenic mouse mammary glands was free of maspin mRNA signal.
Discussion
We showed that TGF-a overexpression in adult transgenic mice induced hyperproliferation, hyperplasia, and occasional carcinoma in mammary gland. Both immunohistochemistry and in situ hybridization analyses demonstrated a down-regulation of maspin expression in the mouse mammary tumor progression. Our data is consistent with the previous ®nding that maspin expression is down-regulated in human breast carcinoma and further support a tumor suppressive role of maspin. In view of several remaining critical issues, the MMTV/TGF-a transgenic mouse model oers the following unique advantages.
The MMTV/TGF-a transgenic model is of choice for studying the in vivo expression pro®le and regulation of maspin in mammary tumor progression. We showed that overexpression of TGF-a is not sucient to cause the malignant phenotype. It is conceivable that complex secondary events are needed in the development of the heterogeneous multi-stage mammary neoplasia. Thus, MMTV/TGF-a transgenic mouse model is likely to provide a broad spectrum of pathological changes similar to those involved in naturally occurring human breast cancer. Compared to the tumor xenograft mouse models that have been successfully used to evaluate the eect of maspin in tumor intervention, MMTV/TGF-a transgenic mice undergo slower multi-stage carcinogenesis, thus may be a unique tool for testing the potential application of maspin in tumor prevention as well as the diagnostic/ prognostic value of maspin as a molecular marker.
Since maspin is abundantly expression in the normal mammary epithelial cells both in the nontransgenic and the MMTV/TGF-a transgenic mice, it is unlikely that TGF-a directly activates or inactivates the maspin transcription. It been noted that maspin expressed in normal human mammary gland is primarily colocalized with myoepithelial cells Sternlicht et al., 1997) . Sternlicht et al. hypothesized that myoepithelial cells are a natural defense against malignancy (Sternlicht et al., 1997) . Interestingly, in mouse mammary gland, both luminal epithelial cells and myoepithelial cells showed strong immunoreactivity with the maspin antibody (Figure 2 ) and were tested positive for maspin mRNA (Figure 4) . It remains to be determined whether the luminal epithelial cells in mouse mammary gland are subject to the same regulation as in human mammary gland. Nonetheless, mammary carcinoma in situ of both human and mouse origin (Figures 2 and 4) show a reduced level of maspin expression. Furthermore, in both human and mouse (Figure 3) , the loss of maspin expression correlates with the transition to invasive carcinoma. These data suggest that the molecular mechanisms underlying the dierential expression of maspin in human and mouse are similar.
Previous in vitro promoter activity analyses indicate that p53 directly activates the transcription of maspin (Zou et al., 2000) . Our current evidence that maspin expression is dierentially regulated in TGF-a induced mammary carcinogenesis opens a new window of possibilities regarding the upstream molecular pathways that regulate maspin expression. In particular, we showed that MMTV/TGF-a transgenic mice expressed maspin in normal and premalignant mammary epithelial cells, but lost maspin expression at the transition from noninvasive tumor to invasive breast carcinoma. It is thought that TGF-a exerts its stimulatory eect on mitosis by activating the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) (Humphreys and Hennighausen, 2000) . Interestingly, several recent studies suggest that TGF-a induced tumorigenecity may directly involve p53. The elegant studies of Wagner et al. (2001) and Lin and Lowe (2001) suggest that TGF-a overexpression may lead to a transient upregulation of p53 via the ras oncogene, and subse- quently lead to the loss of p53 due to genetic instability prior to malignancy (Wagner et al., 2001; Lin and Lowe, 2001) . Taken together, it is possible that the dierential expression of maspin in TGF-a induced mammary carcinogenesis is regulated, at least in part, by p53 at this critical stage of tumor progression.
It is important to point out that since several in vitro studies also suggest that maspin expression may be hormonally regulated Yamada et al., 2000) , the transcriptional regulation of maspin expression may be more complex. Future hypothesisdriven analyses using both TGF-a transgenic mice and human tissue specimens need to be conducted in parallel with in vitro promoter activity analyses in order to evaluate the roles of candidate regulating molecules in maspin transcriptional. In addition, to better assess the biological signi®cance of maspin in breast tumor progression, the correlation of maspin with other molecular markers of breast cancer such as estrogen receptor (ER), HER2 and p53 need to be established.
The MMTV/TGF-a transgenic mouse model may also facilitate the elucidation of the molecular mechanism of maspin. Accumulated evidence supports a role of maspin as an inhibitor of tumor invasion. At the molecular level, it has been shown that maspin speci®cally inhibits bound-plasminogen activators (both tissue-type and urokinase-type) (Sheng et al., 1998; McGowen et al., 2000) . Thus, it is hypothesized that maspin inhibits tumor cell invasion by inhibiting the plasminogen activator-mediated proteolysis. By crossing various genetically modi®ed mice, one can test in vivo functional interaction between maspin and plasminogen activator(s). In parallel, the MMTV/TGFa transgenic model could be used to evaluate whether the expression of maspin is correlated with that of its candidate target molecules such as urokinase-type plasminogen activator (uPA) in the natural tumor progression.
In conclusion, we found a direct correlation between down-regulation of maspin expression and the stage of mammary tumors in MMTV/TGF-a transgenic mice. Our data suggests that MMTV/TGF-a transgenic mouse model is advantageous for in vivo evaluation of both the expression and the biological function of maspin during the slow mutli-stage carcinogenesis of mammary gland.
Materials and methods

Generation and characterization of MMTV/TGF-a transgenic mice
The construction of MMTV LTR was similar to the previously published work of (Matsui et al., 1990) . In brief, pMMTV/TGF-a, the SV40 early promoter region in the vector pKCR was replaced by the complete MMTV-LTR. A 925 bp human TGF-a cDNA (kindly provided by Dr Bell, University of Chicago) was then inserted into EcoRI site of b-glonin exon 3. The 3.6 kb XhoI fragment was puri®ed and microinjected into (C57BL X DBA) fertilized eggs. Homozygous TGF-a transgenic mice were obtained by breeding two heterozygous TGF-a transgenic mice. For histological examination of the mammary glands, the skin containing the mammary fat pads was ®xed in 10% buered formalin for at least 24 h and then embedded in paran. Routinely, 5 mm sections of the whole mount tumor and mammary tissue were stained with hematoxylin and eosin using a standard protocol.
RNase protection assay
To con®rm the expression of the TGF-a transgene, RNase protection assay was performed as described previously (Reddy et al., 1994) . Brie¯y, the TGF-a probe used for RNase protection analysis was 152-bp SphI-ApaI fragment cloned in antisense orientation into pGEM7zf (provided by Dr Kern, Lombardi Cancer Center, Washington, DC, USA). The resulting plasmid was linearized with BamHI and transcribed with T7 polymerase in the presence of 32 P-labeled ATP. Thirty micrograms of total RNA from each sample were hybridized overnight at 508C with 50 000 c.p.m. of probe in 30 ml of buer containing 80% formamide, 40 mM piperazine-N,N'-bis(2-ethanesulfonic acid), 0.4 M NaCl, and 0.1 M EDTA. Samples were subsequently digested with 40 mg/ml RNase A (Sigma) for 30 min at 258C. Digestion was terminated with proteinase K and SDS. The samples were pelleted and resuspended in 5 ml of an 80% formamide loading buer and run on 6% polyacrylamide sequencing gel with 8 M urea. Size markers were prepared by end labeling MspI-digested fragments of pBR322. The gels were dried and exposed to X-ray ®lm in the presence of an intensifying screen at 770 8C for 1 or 2 days.
Immunohistochemistry
The expression of maspin protein was immunostained by using AbS4A, a polyclonal antibody raised against the unique reactive loop sequence of maspin , on 5-mm sections cut from the aforementioned tissue blocks. The immunohistochemical staining was performed at room temperature unless otherwise stated for a speci®c step. The slides were deparanized in xylene and rehydrated in graded ethanols to PBS. Endogenous peroxidase activity was destroyed by treating the tissue for 10 min in 1% H 2 O 2 in methanol. Antigen was retrieved in 10 mM sodium citrate (pH 6.0) by microwave heating for 3 min in the case of surgical specimens and for 5 min on the whole mount autopsy tissues. Following the initial blocking with 10% normal goat serum for 30 min, the primary antibody was applied at 4.0 mg/ml with 1% BSA and 0.01% Triton-X100 and allowed to incubate overnight at 48C. The tissues were then blotted with biotinylated anti-rabbit secondary antibody (Zymed) for 30 min, and subsequently with strepavidin-HRP (Zymed). The DAB color reaction was employed for detection according to the manufacturer's directions (Vector). The slides were counterstained with hematoxylin and dehydrated in a series of graded ethanols and xylene followed by mounting with Permount (Fisher). The negative controls of immunohistochemical staining were performed in the similar fashion except that puri®ed preimmune IgG at a ®nal concentration of 4 mg/ml was used in the place of Abs4A.
In-situ hybridization
The PCR-ampli®ed full length coding sequence of maspin cDNA in the pGEM7Zf(+) vector (Xia et al., 2000) was used as the template for in vitro transcription with the DIG labeling kit (from Boehringer Mannheim, Indianapolis, IN, USA). The resulting labeled full-length maspin mRNA was hydrolyzed to approximately 0.2 kb fragment, then used in the subsequent in situ-hybridization procedure. The DIGlabeled full-length sense strand maspin mRNA was used in parallel as the negative controls.
The in situ hybridization was performed as described by the manufacturer with some modi®cations. Brie¯y, tissue specimens were deparanized in xylene and rehydrated through a series of graded ethanols to PBS. Following the permeabilization with 25 mg Proteinase K in Tris/EDTA buer (pH 8.0) for 30 min at 378C, the specimens were denatured with 46SCC in 50% deionized formamide at 378C for 10 min. The slides were then hybridized with 5 ± 10 ng of DIG labeled probe overnight at 608C, followed by two washes with 0.16SCC at 608C (with agitation). The speci®cally bound DIG-labeled DNA was detected by the color reaction of the horse-radish peroxidase-conjugated anti-DIG antibody. The sections are then counter stained with methyl green and mounted with Permount.
